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Follow-up of loci from the International Genomics of
Alzheimer’s Disease Project identifies TRIP4 as a novel
susceptibility gene
A Ruiz1,32, S Heilmann2,3,32, T Becker4,5,32, I Hernández1, H Wagner6, M Thelen6, A Mauleón1, M Rosende-Roca1, C Bellenguez7,8,9,
JC Bis10, D Harold11, A Gerrish11, R Sims11, O Sotolongo-Grau1, A Espinosa1, M Alegret1, JL Arrieta12, A Lacour4, M Leber4, J Becker6,
A Lafuente1, S Ruiz1, L Vargas1, O Rodríguez1, G Ortega1, M-A Dominguez1, IGAP33, R Mayeux13,14, JL Haines15,16, MA Pericak-Vance17,18,
LA Farrer19,20,21,22,23, GD Schellenberg24, V Chouraki23, LJ Launer25, C van Duijn26,27,28, S Seshadri23, C Antúnez29, MM Breteler4,
M Serrano-Ríos30, F Jessen4,6, L Tárraga1, MM Nöthen2,3, W Maier4,6, M Boada1,31 and A Ramírez2,6
To follow-up loci discovered by the International Genomics of Alzheimer’s Disease Project, we attempted independent replication
of 19 single nucleotide polymorphisms (SNPs) in a large Spanish sample (Fundació ACE data set; 1808 patients and 2564 controls).
Our results corroborate association with four SNPs located in the genes INPP5D, MEF2C, ZCWPW1 and FERMT2, respectively. Of
these, ZCWPW1 was the only SNP to withstand correction for multiple testing (P= 0.000655). Furthermore, we identify TRIP4
(rs74615166) as a novel genome-wide significant locus for Alzheimer’s disease risk (odds ratio = 1.31; confidence interval 95%
(1.19–1.44); P= 9.74 × 10−9).
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INTRODUCTION
Alzheimer’s disease (AD) is a complex multifactorial neuropsychia-
tric disorder whose etiology involves both environmental and
genetic factors. The major genetic risk factor for AD is the
apolipoprotein E4 (APOE4) allele.1 For 17 years after its discovery,
this remained the only confirmed genetic risk factor for the
disorder. However, subsequent meta-analyses of genome-wide
association studies identified further genetic risk loci. These
include signals close to, or within, candidate genes such as
CLU,2,3 PICALM,2 CR1,3 BIN1,4 ABCA7,5 EPHA1,5,6 CD33,5,6 CD2AP5,6
and ATP5H/KCTD2,7 as well as the MS4A gene cluster.5,6,8
The International Genomics of Alzheimer’s Disease Project
(IGAP) is the largest genetic epidemiology investigation of AD risk
to date. In 2013, the IGAP reported a mega meta-analysis, which
was divided into a discovery step (stage 1) and a replication step
(stage 2). This mega meta-analysis comprised 74 046 samples,
including those of 25 580 AD cases, and identified 11 new loci,
thus doubling the number of genome-wide significant loci
reported for AD.9 The analysis also identified 13 suggestive loci.
These findings may serve as the starting point for novel
discoveries in future AD genomics studies.
Four of the 11 genome-wide significant loci in the IGAP analyses
reached significance in stage 1 (rs8093731 DSG2; rs28834970
PTK2B; rs11218343 SORL1; rs10498633 SLC24A4). The remaining
seven only reached genome-wide significance in stage 2—that is,
after the inclusion of the replication sample (rs35349669 INPP5D;
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rs190982 MEF2C; rs2718058 NME8; rs1476679 ZCWPW1;
rs10838725 CELF1; rs17125944 FERMT2, and rs7274581 CASS4).
Replication of the IGAP findings in an independent series is
therefore warranted. The present report describes the follow-up of
10 novel and nine suggestive IGAP loci using subjects drawn from
the Spanish Fundació ACE cohort.7
MATERIALS AND METHODS
Patients and controls
The present study involved 4372 individuals. These included 1 808 patients
with a possible or probable diagnosis of AD, as assigned by a
neurologist,8,10 and 2564 unrelated healthy controls from the Spanish
general population who were selected from the Neocodex bio-bank.11 The
Table 1. Results for the 19 IGAP SNPs in the Fundació ACE data set
SNP Chr. Base pair Maj/min
allele
Locus IGAP
status
OR (IGAP) MAF
(IGAP)
OR (F.ACE) MAF
(F.ACE)
P-value
(F.ACE)
OR
(com)
P-value
(com)
Het*
rs8093731 18 29088958 C/T DSG2 NL-ST 1 0.73
(0.62–
0.86)
0.017 0.728
(0.486–
1.090)
0.011 0.1217 0.7292 3.02 × 10−5 0.0006
rs28834970 8 27195121 T/C PTK2B NL-ST 1 1.10
(1.08–
1.13)
0.366 0.975
(0.893–
1.065)
0.372 0.571 1.0936 2.39
×10− 12
0.026
rs11218343 11 121435587 T/C SORL1 NL-ST 1 0.77
(0.72–
0.82)
0.039 0.864
(0.678–
1.099)
0.035 0.233 0.7757 6.91
×10− 15
0.6301
rs10498633 14 92926952 G/T SLC24A4 NL-ST 1 0.91
(0.88–
0.94)
0.217 0.922
(0.827–
1.028)
0.191 0.1418 0.9107 1.99 ×10− 9 0.6781
rs7274581 20 55018260 T/C CASS4 NL-ST 2 0.88
(0.84–
0.92)
0.083 1.017
(0.882–
1.173)
0.098 0.8153 0.8888 1.75 ×10− 7 0.1372
rs35349669 2 234068476 C/T INPP5D NL-ST 2 1.08
(1.05–
1.11)
0.488 1.104
(1.014–
1.203)
0.439 0.02314 1.0807 2.59 ×10− 9 0.5807
rs2718058 7 37841534 A/G NME8 NL-ST 2 0.93
(0.90–
0.95)
0.373 1.081
(0.992–
1.178)
0.418 0.1201 0.9368 2.41 ×10− 7 0.0044
rs190982 5 88223420 A/G MEF2C NL-ST 2 0.93
(0.90–
0.95)
0.408 0.885
(0.811–
0.966)
0.388 0.006285 0.9232 1.18 ×10− 9 0.5718
rs17125944 14 53400629 T/C FERMT2 NL-ST 2 1.14
(1.09–
1.19)
0.092 1.238
(1.036–
1.478)
0.060 0.01851 1.1470 6.71
×10− 10
0.5585
rs1476679 7 100004446 T/C ZCWPW1 NL-ST 2 0.91
(0.89–
0.94)
0.287 0.846
(0.769–
0.932)
0.271 0.000655 0.9147 5.04
×10− 12
0.1727
rs9381040 6 41154650 C/T TREML2 SUG 0.93
(0.91–
0.96)
0.297 0.991
(0.901–
1.089)
0.277 0.8446 0.9365 1.30 ×10− 6 0.2321
rs8035452 15 51040798 T/C SPPL2A SUG 0.93
(0.91–
0.96)
0.339 1.102
(1.009–
1.204)
0.362 0.03098 0.9455 1.99 ×10− 5 0.001
rs7920721 10 11720308 A/G ECHDC3 SUG 1.07
(1.04–
1.10)
0.387 1.049
(0.962–
1.145)
0.395 0.2778 1.0696 1.68 ×10− 7 0.8768
rs7818382 8 96054000 C/T NDUFAF6 SUG 1.07
(1.04–
1.10)
0.469 1.003
(0.921–
1.093)
0.455 0.9405 1.0657 2.48 ×10–7 0.3428
rs74615166 15 64725490 T/C TRIP4 SUG 1.29
(1.17–
1.42)
0.02 1.519
(1.148–
2.012)
0.023 0.003265 1.3102 9.74 ×10− 9 0.1357
rs7295246 12 43967677 T/G ADAMST20 SUG 1.07
(1.04–
1.10)
0.406 1.044
(0.958–
1.139)
0.399 0.3253 1.0693 2.23 ×10− 7 0.764
rs7225151 17 5137047 G/A SCIMP SUG 1.10
(1.06–
1.15)
0.121 0.952
(0.839–
1.081)
0.129 0.4475 1.0898 3.06 ×10− 6 0.0751
rs6678275 1 193625233 G/C None SUG 1.09
(1.05–
1.13)
0.169 0.948
(0.849–
1.059)
0.180 0.3419 1.0775 4.21 ×10− 6 0.0444
rs6448799 4 11630049 C/T HS3ST1 SUG 1.08
(1.05–
1.11)
0.300 0.994
(0.905–
1.091)
0.293 0.9006 1.0729 2.70 ×10− 7 0.247
Abbreviations: Chr, chromosome; F.ACE, Fundació ACE data set; IGAP, International Genomics of Alzheimer’s Disease Project; MAF, minor allele frequency; Maj/
Min allele: major and minor allele; NL-ST 1, new locus in stage 1 of IGAP study; NL-ST 2, new locus in stage 2 of IGAP study; OR, odds ratio; SNP, single
nucleotide polymorphism; SUG, suggestive locus. Het*: P-value Brelow-day test.
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AD cases were recruited consecutively from three centers: Barcelona
(n=1627); Madrid (n= 161); and Murcia (n=20). None of these AD patients
had been included in the IGAP replication analyses. To avoid the issue of
population stratification, all cases and controls were of Spanish ancestry,
which was defined as a history of two generations of registered Spanish
ancestors. The demographic characteristics of the Fundació ACE partici-
pants are described elsewhere.7 Written informed consent was obtained
from all participants, or from their legal representatives when necessary.
The study was approved by the respective ethics committees, and was
performed in accordance with the Code of Ethical Principles for Medical
Research Involving Human Subjects of the World Medical Association.
DNA isolation and genotyping
DNA was extracted using ‘Magnapure’ technology (Roche Diagnostics,
Mannheim, Germany). Twenty-five single nucleotide length polymorph-
isms (SNPs) with an AD-association risk of below Po10−6 in the IGAP
consortium study were selected for replication. The primer molecules for
the multiplex reaction were designed using the Assay Design Suite tool
(www.mysequenom.com, Sequenom, San Diego, CA, USA). Assay designs
were successful for 21 of the 25 selected variants. Four SNPs (rs72807343
(SQSTM1); rs9271192 (HLA-DRB5/HLA-DRB1); rs2337406 (IGH@); and
chr17:61,538,148 (ACE)) were rejected during this phase due to technical
problems. Primer sequences and assay conditions for the genotyped SNPs
are available upon request.
Quality control
A total of 1808 AD patients and 2564 controls were genotyped for 21 SNPs
using Sequenom's Mass Array System (Sequenom) and iPlex Gold reagents
in accordance with the manufacturer's instructions. Only SNPs with a call
rate of ⩾95% and a Hardy–Weinberg equilibrium P-value of >0.01 in the
whole data set were included in the subsequent analyses (Supplementary
Table 1). All SNP major and minor alleles and allelic frequencies obtained in
the Fundació ACE data set were fully consistent with those reported by the
IGAP consortium (Table 1). The overall conversion rate was 96.7%. The
SNPs rs10751667 (AP2A2) and rs10838725 (CELF1) failed quality control and
were excluded from the statistical analyses. The 19 successfully genotyped
SNPs and their status in the IGAP analyses (that is, genome-wide
association studies significant or suggestive) are specified in Table 1.
Statistical analysis
Genetic association analyses and calculation of allelic frequencies and
Hardy–Weinberg equilibrium were conducted using the online tool at the
TUM Helmholtz Center (Munich, Germany; http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl). Briefly, tests adapted from those of Sasieni12 were used. Age- and
sex-adjusted binary logistic regression analyses were performed using SPSS
15.0 software (SPSS, Chicago, IL, USA). In addition, Mantel–Haenzsel-
stratified analyses were conducted according to gender and the presence
or absence of the APOE-ε4 allele (Supplementary Tables 2 and 3,
respectively). Breslow-day tests were conducted to measure the signifi-
cance of SNP×APOE and SNP×gender interactions. All SNP calculations
were double-checked using PLINK or INTERSNP software.13,14 Meta-analyses
were conducted using the PLINK software. All results were doubled-
checked using Ken Rothman’s Episheet spreadsheet and PLINK (for details
see http://pngu.mgh.harvard.edu/~purcell/plink/; http://krothman.hostbyet2.
com/episheet.xls). Power calculations were performed using Episheet.
RESULTS AND DISCUSSION
In the present replication effort, a nominally significant signal
(Po0.05) was detected for six of the 19 investigated SNPs:
rs35349669 at INPP5D (P= 0.023); rs190982 at MEF2C (P= 0.0062);
rs1476679 at ZCWPW1 (P= 0.00065); rs17125944 at FERMT2
(P= 0.018); rs8035452 at SPPL2A (P= 0.031); and rs74615166 at
TRIP4 (P= 0.0032) (Table 1). Of these, rs1476679 at the ZCWPW1
locus, which had shown genome-wide significance in stage 2 of
the IGAP analyses, was the only SNP to withstand correction for
multiple testing (P= 0.000655). However, the observed inflation
factor for χ2 was λ= 4.7. As in genome-wide analyses, the λ-value
was computed as the median of the χ2-test statistics obtained for
the 19 investigated SNPs. Under the null hypothesis of no
association, the expected λ value is 1 in the absence of true
association. In our study, however, the λ value is 4.7, which is a
strong sign of an overall increased degree of significant
associations for the SNPs investigated in the Spanish cohort. In
the present context, the λ value is considered to indicate the
overall degree of positive associations for a small set of SNPs, in
contrast to the genome-wide setting, where it is used as an
indicator of residual inflation caused by spurious association. Thus,
the present observations in our study are unlikely to represent
chance findings. Furthermore, four of these five nominally
significant association signals displayed the same effect direction
as that reported by the IGAP (Table 1). The exception was the
marker rs8035452. The IGAP reported this as a suggestive signal.
However, an effect in the opposite direction was found in the
Fundació ACE data set. This observation might reflect a lack of
power in our data set to detect this signal. Alternatively, the
original finding may represent a false-positive.
No significant association was found for three of the four
genome-wide significant loci detected during IGAP Stage 1
(rs11218343 at SORL1; rs10498633 at SLC24A4; rs8093731 at DSG2).
However, since the effect sizes and directions of these three loci
were fully consistent with those reported by the IGAP, our failure to
replicate them may have been attributable to a lack of power.
In total, seven of the 10 investigated genome-wide significant
loci from the IGAP displayed a consistent effect in the present data
set. The non-consistent effects observed for the NME8, PTKB2, and
CASS4 signals may have been attributable to a lack of power. It
should be noted that, although our series may appear under-
powered compared with the IGAP data set, the present study had
on average a power of 45% to detect each of the genome-wide
association studies significant signals reported by the IGAP.
The results of the APOE and gender-adjusted stratified analyses
suggested that for most of the 19 investigated SNPs, APOE status
and gender had little impact on effect size or the association
results (Supplementary Table 3). Interestingly, nominal P-values for
APOE interaction were obtained for two nonsignificant SNPs in our
series (rs7295246 ADAMST20; and rs7225151 SCIMP). Both loci
were reported as being suggestive by the IGAP. The results of the
present stratification analyses support the hypothesis that these
two loci represent susceptibility factors in only a fraction of AD
patients, and that their effects are dependent upon the APOE-ε4
genotype. This observation may facilitate determination of their
role in AD development in future studies (Supplementary Table 3).
Of the nine suggestive loci proposed by the IGAP, only one SNP
was significant in the present analyses (Table 1). The statistically
significant signal was obtained for rs74615166 at the thyroid
receptor interacting protein gene 4, TRIP4, locus (odd ratio = 1.519
(1.148–2.012), P= 0.0032). This variant had a minor allele
frequency of 0.02 in both the IGAP and the Fundació ACE
(Table 1). Interestingly, a larger effect size was observed in the
Fundació ACE data set than in the IGAP. However, an advantage of
the present analyses was that this SNP was genotyped directly,
whereas the IGAP had to rely in part on imputed genotypes. Since
imputation for rarer variants is more difficult, this might explain
why a stronger effect was observed in the present cohort. The
present findings for the nine suggestive IGAP signals may indicate
that these loci have a weaker effect on AD risk than the genome-
wide significant SNPs. As a direct consequence, the power to
detect them using our data set is relatively low (33% on average
for suggestive signals). However, our data set had a >99.9% power
to detect at least one suggestive locus (0.33),9 thus explaining the
results for the TRIP4 locus.
Meta-analysis of the present results with the IGAP meta-analysis
data identified TRIP4 as a novel genome-wide significant locus.
The new susceptibility AD SNP is located within the eleventh
intron of TRIP4 (15q22.31; rs74615166; OR= 1.31 (1.17–1.42),
P= 9.74 × 10−9; Table 1). According to publicly available databases
(genome.cse.ucsc.edu), TRIP4 is highly expressed in the immune
system and has been detected in various tissues, including the
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brain. Research suggests that TRIP4 is a component of the nuclear
receptor-coupled co-activation machinery that enables or disables
DNA transcription.15 A homolog of the TRIP4 gene in Caenorhab-
ditis elegans showed elevated transcript levels in aged or starved
adults, which suggests that TRIP4 has a role in cellular
maintenance or survival.16 The TRIP class of proteins show thyroid
hormone-dependent interaction with their receptors, and the
association between TRIP4 and AD risk may partly explain previous
findings of an association between low thyroid-stimulating
hormone levels in clinically euthyroid subjects and increased AD
risk.17 TRIP proteins show a similar ligand-dependent interaction
with the retinoid X receptor. This is of interest, since a recent AD
mouse model study reported that administration of the retinoid X
receptor agonist bexarotene resulted, within hours, in enhanced
clearance of soluble Aβ.18 Besides TRIP4, the linkage disequili-
brium block that contains rs74615166 includes several other
candidate genes, such as CSNK1G1. CSNK1G1 is a member of the
CK-1 family, and its gene product has been implicated in the
amyloid cascade.19
A major limitation of the present study was the lack of power to
confirm all true associations. Therefore, our negative results
cannot be interpreted as confirmation of a lack of association
for the respective SNPs, which remain putative susceptibility loci
for AD. A fraction of the suggestive SNPs reported by the IGAP
may be genuine, and these SNPs warrant further investigation.
The results obtained for TRIP4 underscore the importance of
follow-up and comprehensive replication of consortia results.
Further genotyping and re-sequencing efforts to investigate TRIP4
and the other IGAP loci are underway in order to elucidate the role
of TRIP4 in AD risk and corroborate further genuine signals.
Further studies are now warranted to identify the functional
mechanism underlying the association between TRIP4 and AD.
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